ABACUS TPN CALCULATING SOFTWARE
Report
- Report Number
- 1419106-2007-00009
- Event Type
- Other
- Date Received
- September 7, 2007
- Date of Event
- August 11, 2007
- Report Date
- August 11, 2007
- Manufacturer
- BAXA CORPORATION
- Product Code
- LNX
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- NV, US
- Reporter Occupation
- PHARMACIST
Narratives
A REVIEW OF THE ORDER FORM AND THE DATABASE REVEALED THAT THE SOFTWARE FUNCTIONED AS DESIGNED. THE SAFETY FEATURES (INGREDIENT VOLUME WARNINGS) RESIDENT IN THE SOFTWARE WERE NOT PROPERLY EMPLOYED. THE VERIFICATION LABEL ALONG WITH THE ASSOCIATED DOCUMENTATION THAT IS PRODUCED WITH THE ORDER OF THE TPN BAG CLEARLY INDICATE THE VOLUME OF RANITIDINE IN THE TPN SOLUTION; PHARMACIST AND PHYSICIAN VERIFICATION OF THE TPN BAG FAILED TO IDENTIFY THE HIGHER -THAN-DESIRED ORDERED AMOUNT OF RANITIDINE. A REVIEW OF THE PRODUCT HAZARD ANALYSIS (PHA) AND CUSTOMER COMPLAINT DATA FOR THIS PRODUCT WAS CONDUCTED, AND IT WAS DETERMINED THAT THIS ISSUE NOT OCCURRING WITH GREATER FREQUENCY OR SEVERITY THAN IS EXPECTED FOR THE DEVICE, AS DOCUMENTED IN THE PHA.
IN 2007, BAXA WAS NOTIFIED OF AN INCIDENT THAT RESULTED IN A PATIENT REQUIRING ADDITIONAL MONITORING FOR POTENTIAL SIDE EFFECTS FROM AN OVER DOSE OF RANITIDINE (ZANTAC). THE CUSTOMER REPORTED THAT WHILE USING THE ABACUS TPN CALCULATING SOFTWARE FOR CREATING A TPN SOLUTION, THAT A PATIENT WAS INFUSED WITH A TPN SOLUTION THAT CONTAINED A HIGHER-THAN-DESIRED VOLUME OF RANITIDINE (ZANTAC) FOR THIS PARTICULAR PATIENT. THE DOSE OF RANITIDINE (ZANTAC), RATHER THAN BEING 24MG/DAY WAS ENTERED AS 24MG/KG, APPROXIMATELY 7.6 TIMES THE ORIGINAL ORDERED AMOUNT. THE CUSTOMER REPORTED THAT NO ADVERSE EVENT RESULTED FROM THE OVER-DELIVERY OF RANITIDINE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1 | ABACUS TPN CALCULATING SOFTWARE | ABACUS SINGLE WORK STATION | LNX | BAXA CORPORATION | 8300-0046 | NA |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | YR | Required Intervention |